Critically, our data mining revealed several significant AEs not listed in FTD/TPI product labeling, such as iron deficiency, intestinal obstruction, ascites, small intestinal obstruction, ileus, intestinal perforation, intra-abdominal fluid collection, obstruction, hepatic failure, cholangitis, product dose omission in error, stoma site haemorrhage, carcinoembryonic antigen increased, blood iron decreased, blood magnesium decreased, dehydration, product distribution issue, product packaging quantity issue, hydronephrosis, ureteric obstruction, transfusion, stent placement and radiotherapy. The gene discussed is CEACAM5; the disease is Hepatic failure.